Allegation: Secret Memo To Keep Money Flowing To Family

Massachusetts AG FAC ¶237:

Mortimer Sackler a secret memo about how to keep money flowing to their family. Richard wrote that Purdue's business posed a "dangerous concentration of risk." After the criminal investigations that almost reached the Sacklers, Richard wrote that it was crucial to install a CEO who would be loyal to the family: "People who will shift their loyalties rapidly under stress and temptation can become a liability from the owners' viewpoint." Richard recommended John Stewart for CEO because of his loyalty. Richard also proposed that the family should either sell Purdue in 2008 or, if they could not find a buyer, milk the profits out of the business and "distribute more free cash flow" to themselves.

helped them convince area doctors to prescribe the highest Purdue received 853 Reports of Concern about abuse and 8, and they had conducted only 17 field inquiries in eklers that they received 83 tips to Purdue's compliance report any of them to the authorities. ¹⁵¹ lers that they promoted Purdue's opioids at Tufts Health sk Management in Boston on March 27, ¹⁵² ackler sent Kathe, Ilene, David, Jonathan, and Mortimer sep money flowing to their family. Richard wrote that concentration of risk." After the criminal investigations

iff their loyalties rapidly under stress and temptation can wooint." Richard recommended John Stewart for CEO

oposed that the family should either sell Purdue in 2008 the profits out of the business and "distribute more free

obtained data showing which pharmacies stocked

235. In April, staff told the Sacklers that Purdue employed 304 sales reps. Staff

78

 ²⁰⁰⁸⁻⁰³⁻¹⁵ Board report, pgs. 17, 23, 24, 27, PDD8901724450, -456, -457, -460.
 2008-03-15 Board report, pg. 16, PDD8901724449.

¹⁵³ 2008-04-18 email and attached memo from Richard Sackler, PDD9316300629-631.

Cited Document: Confidential Memo About CEO Hiring

- CEO loyalty in context of sale of business or recap
- No reference to prior criminal investigation

Re: CEO Considerations

The Purdue CEO and his top team are thus in an interesting and potentially conflicted position. Under some circumstances, such as a merger with a public company, they may gain exceptional opportunities to increase personal wealth through equity packages. On the other hand, they may at the end of the day gain only the one-time benefits specified in change-of-control or severance agreements.

- "Concentration of risk" wealth in single company dependent on single product with 2013 patent cliff
- "Major risks must be avoided, especially non-compliance with the Corporate Integrity Agreement...."
- The only litigation risk discussed concerns patent exclusivity for OxyContin

nd or whether they are well cost inmal ha bly, there will be intense the Company er cinner — pecomes s toop a who will shift their e a liability from the unly shoring in this the cush flow afforded by through our period of exchaighty, currently estimated to be through 2013. Trum at be remembered that we need a sout pediatrio studies to earn the audition of 6 munits of patent life or the engine's teleparated by necomplish approval 1. This must be proceed through operational excellence and astate positioning versus potential competitors. M. jm instance to be avoided, especially non-contributes with the Commute hitegrity Agreement, and comployee loss of confidence in a period of nutral once. Priority 2. Building an organization and business systems that will improve efficiency and decision-making, while frimming redundant procedures or staff The containsation can reorganization of the Company, including top executive ranks, is a priority. In particular, the absence of a Chief Scientific Officer to connect a and prioritize R&D programs is a casjon gap, and the question has been raised whether Business Development should be fed by a more seasoner, executive if we are to HIGHLY CONFIDENT AL P4572311 PDD9316314310 HIGHLY CONTIDENT A LACCEDS REOTE CITED BY COURT ORDER

NICEMMONWEALTH OF KENT JOKY, BY RELIGION CONTINUES GENERALLY SURGUE PHARMALEF ET AL

O'VE ACTION NO. 37 C. 01303 (PINC COURTY CIRCUIT) COURT.

CYLATION NO. 37 C. 01303 (PINC COURTY CIRCUIT) COURT.

Probable investors in, or accurate or, if undie on it was the too management boar rifficiently. Prosiver resolutional management boar rifficiently. Prosiver resolution will include the company as an alement of value. On the after hand, some stratego buyer's which controlled sprengers and intendition provides associated in the course port in the course port and systems.

> a merger with a public trease personal wealth at the end of the day day

4/08 CEO Considerations Memo, p. 2 (PDD9316314309)